Vnitřní lékařství 4/2020

KAZUISTIKA Srdcové zlyhávanie ako prejav akromegálie E50 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(2): e46–e50 /  www.casopisvnitrnilekarstvi.cz LITERATÚRA 1. Capatina C, Wass JH 60 Years Of Neuroendocrinology: Acromegaly. J Endocrinol 2015; 226: 141–160. 2. Sharma MD, Nguyen AV, Brown S et al. Cardiovascular disease in acromegaly. Huo‑ stonmethodist.org/debakey‑journal 2007; 2: 64–67. 3. Matta MP, Caron P Acromegalic cardiomyopathy: a review of the literature. Pituitary 2003; 6: 203–207. 4. Kršek M Endokrinni choroby a jejich vliv na KV system. Medical Tribune 2015; XXX: 17. 5. Mosca S, Paolillo S, Colao A et al. Cardiovascular involvement inpatients affected by acromegaly: an appraisal. Int J Cardiol 2013; 167: 1712–1718. 6. Kahaly G, Olshausen KV, Mohr‑Kahaly S et al. Arrhythmia profile in acromegaly. Eur He‑ art J 1992; 13: 51–56. 7. Vitale G, Pivonello R, Lombardi G et al. Cardiacabnormalities in acromegaly. Pathophys‑ iology and implicationsfor management. Treat Endocrinol 2004; 3: 309–318 8. Warszawski L, Kasuki L, Sá R et al. Low frequencyof cardiac arrhythmias and lack of structural heart disease inmedically‑naďve acromegaly patients: a prospective study at‑ baseline and after 1 year of somatostatin analogs treatment. Pituitary 2016; 19: 582–589. 9. Roca E, Mattogno PP, Porcelli Tet al. Plurihormonal ACTH‑GH Pituitary Adenoma: Case Report and Systematic Literature Review. World neurosurgery 2018; 114: 158–164. 10. Colao A, Pivonello R, Grasso LF et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 2011; 165: 713–721. 11. Jayasena C, Comninos A, Clarke H et al. The effects of long term GH and IGF‑I exposu‑ re on the development of cardiovascular, cerebrovascular and metabolic co‑morbidities in treated patients with acromegaly. Clin Endocrinol 2011; 75: 220–225. 12. Colao A, Spinelli L, Marzullo P et al. Highprevalence of cardiac valve disease in acromegaly: an observational, analytical, case‑control study. J Clin Endocrinol Metab 2003; 88: 3196–3201. 13. Pereira AM, van Thiel SW, Lindner JR et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89: 71–75. 14. van der Klaauw AA, Bax JJ, Roelfsema F et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 2006; 16: 101–107. 15. Colao A, Marzullo P, Di Somma C et al. Growth hormone and the heart. Clin Endocri‑ nol 2001; 54: 137–154. 16. Isgaard J, Tivesten A, Friberg P et al. The role of the GH/IGF‑I axis forthe cardiac func‑ tion and structure. Horm Metab Res 1999; 31: 50–54. 17. Castellano G, Affuso F, Conza P Di et al. The GH/IGF-1 Axis and Heart Failure. Curr Car‑ diol Rev 2009; 5: 203–215. 18. Mendoza E, Malong CL, Tanchee‑Ngo MJ et al. Acromegaly With Cardiomyopathy, Car‑ diac Thrombus and Hemorrhagic Cerebral Infarct: A Case Report of Therapeutic Dilemma With Review of Literature. Int J Endocrinol Metab 2015; 13: 1–4. 19. John jr. AJ, Laws ER Surgical Treatment of Pituitary Adenomas. Dostupné z https:// www.ncbi.nlm.nih.gov/books/NBK278983/. 20. Hána V, Švancara J, Bandúrová L et al. Registry of sellar tumors - RESET: Diagnostic and therapy of acromegaly in Czech and Slovak republics in the 21st century. Diabetes, me‑ tabolizmus, endokrinologie a výživa 2013; 16: 219–224. 21. Colao A, Pivonello R, Galderisi M et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008; 93: 2639–2646. 22. Sakai H, Tsuchiya K, Nakayama C et al. Improvement of endothelial dysfunction in acro‑ megaly after transsphenoidal surgery. Endocr J 2008; 55: 853–859. 23. Melmed S New therapeutic agents for acromegaly. Nat Rev Endocrinol 2016; 12: 90–98. 24. Katznelson L, Laws EL, Melmed S et al. Acromegaly: An Endocrine Society Clinical Prac‑ tice Guideline. J Clin Endocrinol Metab 2014; 99: 3933–3951. 25. Zahr R, Fleseriu M Updates in Diagnosis and Treatment of Acromegaly. European En‑ docrinology 2018; 10: 57–61. 26. Carmichael JD et al. Acromegaly clinical trial methodology impact on reported bio‑ chemical efficacy rates of somatostatin receptor ligand treatments: a meta‑analysis. J Clin Endocrinol Metab 2014; 99: 1825–1833. 27. Colao A, Marzullo P, Cuocolo A et al. Reversal ofacromegalic cardiomyopathy in young but not in middle‑agedpatients after 12 months of treatment with the depot long acting somatostatin analogue octreotide. Clin Endocrinol 2003; 58: 169–176. 28. Annamalai AK, Webb A, Kandasamy N et al. A comprehensive study of clinical, bio‑ chemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand thera‑ py. J Clin Endocrinol Metab 2013; 98: 1040–1050. 29. Colao A, Marzullo P, Ferone D et al. Cardiovascular effects of depot long‑acting so‑ matostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000; 86: 3132–3140. 30. Colao A, Cuocolo A, Marzullo P et al. Effects of one‑year treatment with octre‑ otide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84: 17–23. 31. Akutsu H, Kreutzer J, Wasmeier G et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 2010; 162: 879–886. 32. Colao A, Auriemma RS, Galdiero M et al. Effects of initial therapy for five years with so‑ matostatin analogs for acromegaly on growth hormone and insulin‑like growth factorI levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocri‑ nol Metab 2009; 94: 3746–3756. 33. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone‑receptor antagonist pegvisomant. N Engl J Med 2000; 342: 1171–1177. 34. van der Lely AJ, Hutson RK, Trainer PJ et al. Long‑term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754–1759. 35. van der Lely AJ, Biller BM, Brue T et al. Long‑term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocri‑ nol Metab 2012; 97: 1589–1597. 36. Colao A, Pivonello R, Auriemma RS et al. Efficacy of 12-monthtreatment with the GH receptor antagonist pegvisomant inpatients with acromegaly resistant to long‑term, high­ ‑dosesomatostatin analog treatment: effect on IGF‑I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006; 154: 467–477. 37. Auriemma RS, Pivonello R, De Martino MC et al. Treatment with GH receptor anta‑ gonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol 2012; 168: 15–22. 38. De Martino MC, Auriemma RS, Brevetti G et al. The treatment with growth hormone receptor antagonistin acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 2010; 33: 663–670. 39. Pivonello R, Galderisi M, Auriemma RS et al. Treatment with growth hormone recep‑ tor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Encocri‑ nol Metab 2007; 92: 476–482. 40. Kuhn E, Maione L, Bouchachi A et al. Long‑term effects of pegvisomant on comor‑ bidities in patients with acromegaly: a retrospective single‑center study. Eur J Endocri‑ nol 2015; 173: 693–702. 41. Auriemma RS, Grasso LF, Galdiero M et al. Effects of long‑term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 2016; 55: 872–884. 42. Baldwin A, Cundy T, Butler J et al. Progression of cardiovascular disease in acrome‑ galic patients treated by external pituitary irradiation. Acta Endocrinol 1985; 1: 581–587. 43. Sninčák M Srdcové zlyhávanie v roku 2016 - novinky v odporúčaniach, súčasný stav, trendy. Via practica 2016; 13: 163–167. 44. Thomas J, Dattani A, Zemrak F et al. Renin‑Angiotensin System. Blockade Improves Cardiac Indices in Acromegaly Patients. Exp Clin Endocrinol Diabetes 2017; 125: 365–367. 45. Bihan H, Espinosa C, Valdes‑Socin H et al. Long‑term outcome of patients with acrome‑ galy and congestive heart failure. J Clin Endocrinol Metab 2004; 89: 5308–5313. 46. Silvermann CB, Baran A Dilated and Restrictive Cardiomyopathies. http://www.cleve‑ landclinicmeded.com/medicalpubs/diseasemanagement/cardiology/dilated‑restrictive­ ‑cardiomyopathy/